Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading Volume - Here's What Happened

Key Points

• Pharming Group's shares experienced a significant trading volume increase, with approximately 4,832 shares traded, though this represents a 6% decline from the previous session.
• The company's latest earnings report showed an EPS of ($0.22), surpassing analyst estimates of ($0.25), and revenues of $79.09 million compared to expectations of $67.74 million.
• Pharming Group has a market capitalization of $707.37 million and maintains a current ratio of 2.76, indicating good short-term financial health.
• Silverberg Bernstein Capital Management raised its stake in Pharming Group by 8.6%, highlighting increasing institutional interest in the company.

Shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) saw unusually-strong trading volume on Friday . Approximately 4,832 shares changed hands during mid-day trading, a decline of 6% from the previous session's volume of 5,120 shares.The stock last traded at $10.17 and had previously closed at $10.19.

Pharming Group Stock Down 0.7%

The company has a market cap of $680.30 million, a P/E ratio of -49.65 and a beta of 0.02. The company has a 50 day moving average of $10.70 and a 200-day moving average of $9.44. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.76 and a quick ratio of 2.00.

Pharming Group (NASDAQ:PHAR - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.03. The firm had revenue of $79.09 million during the quarter, compared to analyst estimates of $67.74 million. Pharming Group had a negative return on equity of 6.01% and a negative net margin of 4.14%. On average, equities analysts predict that Pharming Group N.V. Sponsored ADR will post -0.2 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its stake in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) by 8.6% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 52,147 shares of the company's stock after purchasing an additional 4,150 shares during the quarter. Silverberg Bernstein Capital Management LLC owned approximately 0.08% of Pharming Group worth $557,000 at the end of the most recent quarter. 0.03% of the stock is currently owned by institutional investors and hedge funds.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.